Glyxambi contains a combination of empagliflozin and linagliptin. Empagliflozin and linagliptin are oral diabetes medicines that help control blood sugar levels. Empagliflozin works by helping the kidneys get rid of glucose from your bloodstream. Linagliptin works by regulating the levels of insulin your body produces after eating. Glyxambi is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Glyxambi is also used to lower the risk of death from heart attack, stroke, or heart failure in adults with type 2 diabetes who also have heart disease. This medicine is not for treating type 1 diabetes.
Journal home page: http://www.sciaeon.org/targeted-drug-delivery/home
View Articles: http://www.sciaeon.org/targeted-drug-delivery/current-issue
Share your manuscript: http://www.sciaeon.org/submit-paper
For more queries: drugdelivery@sciaeonopenaccess.com
Journal of Targeted Drug Delivery 